Stay updated on Alirocumab for Plaque Regression in PAD Clinical Trial
Sign up to get notified when there's something new on the Alirocumab for Plaque Regression in PAD Clinical Trial page.

Latest updates to the Alirocumab for Plaque Regression in PAD Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.3 was added to the page, and the HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer/navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe history shows a new revision v3.3.2 replacing the previous v3.2.0. No study details, results, or eligibility information appear to be changed in the provided screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedThe government funding/operating status notice was removed from the page. Core study information and record history remain unchanged.SummaryDifference0.7%

- Check68 days agoChange DetectedThe new screenshot shows minor UI updates to the Record History page, such as a Quality Control banner and tweaks to the version history layout; there are no substantive changes to trial data or status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check97 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference12%

- Check104 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

Stay in the know with updates to Alirocumab for Plaque Regression in PAD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alirocumab for Plaque Regression in PAD Clinical Trial page.